Cvs Health Corp SEC Filings

CVS Health Corporation furnished information from its 2025 Investor Day, where it discussed strategic priorities and updated its financial outlook. On December 9, 2025, the company issued a press release that revised its full-year 2025 financial guidance and introduced full-year 2026 financial guidance. The press release is attached as Exhibit 99.1 to this report and is incorporated into the Regulation FD disclosure section by reference.

The company notes that this press release and related information are being furnished, not filed, under securities laws, meaning they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.

CVS Health Corp executive Tilak Mandadi, EVP and Chief Experience & Technology Officer, reported an automatic share disposition related to equity compensation. On 11/30/2025, he disposed of 6,575 shares of CVS common stock at $80.36 per share. The filing explains this was a surrender of shares to pay withholding taxes due upon the vesting and settlement of a restricted stock unit award, which is a common administrative transaction rather than an open‑market sale. After this tax-related transaction, Mandadi beneficially owned 74,085 CVS shares, held directly.

CVS Health director reported an automatic share disposal related to equity compensation. On 11/30/2025, 9,748 shares of CVS Health common stock were surrendered at a price of $80.36 per share under transaction code "F," which indicates shares withheld to cover taxes on a vesting restricted stock unit award.

After this tax-withholding transaction, the reporting person beneficially owned 19,438.4534 CVS Health shares, held directly. This filing reflects administrative handling of equity award taxation rather than an open-market sale initiated for investment reasons.

CVS Health Corp executive Heidi B. Capozzi reported a tax-related share withholding transaction. On 11/30/2025, she surrendered 9,470 shares of CVS Health common stock at $80.36 per share, coded as an "F" transaction, meaning the shares were withheld to cover taxes due on the vesting and settlement of a restricted stock unit award.

After this transaction, she directly owned 11,415 shares of CVS Health common stock as an executive vice president and Chief People Officer. This event reflects administrative handling of equity compensation rather than an open-market sale.

CVS Health Corp (CVS) director Douglas H. Shulman reported a routine equity compensation transaction. On 11/20/2025, he acquired 1,652 shares of common stock at a price of $76.04 per share, recorded as an "A" (acquired) transaction.

These shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, reflecting standard board compensation rather than an open-market purchase. Following this grant, Shulman beneficially owns 5,929 shares of CVS Health common stock in direct ownership.

CVS Health Corporation director Guy P. Sansone reported receiving common stock as part of his board compensation. On 11/20/2025, he acquired 1,652 shares of CVS common stock at a price of $76.04 per share. The filing explains this stock was issued as payment of a semi-annual retainer at market price under the company’s 2017 Incentive Compensation Plan. Following this grant, Sansone beneficially owns 13,659.355 shares of CVS common stock in direct ownership.

CVS Health Corp (CVS)2,202.788 deferred stock units with a conversion price of $0 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual retainer under the non-employee director compensation policy and are valued at the market price of $76.04 per underlying share of common stock. Each deferred stock unit will convert into one share of CVS common stock and will be issued when the director retires from the Board, as previously elected. Following this transaction, the director beneficially owns 8,080.2915 deferred stock units in direct form.

CVS Health (CVS) director equity grant reported

A CVS Health Corp director filed a Form 4 reporting receipt of 1,652 shares of common stock on 11/20/2025 at a price of $76.04 per share. These shares were issued as payment of a semi-annual board retainer at market price under the company’s 2017 Incentive Compensation Plan, meaning they represent routine director compensation in stock rather than cash.

Following this grant, the director beneficially owns 5,929 CVS common shares, held directly. The filing indicates this was a standard compensation-related issuance, not an open-market purchase or sale.

CVS Health Corp director reports deferred stock unit grant. A CVS Health Corp non-employee director filed a Form 4 reporting receipt of 2,021.9621 deferred stock units on 11/20/2025 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual director retainer and valued at the market price of $76.04 per deferred stock unit.

Each deferred stock unit is to be converted into one share of CVS common stock and issued in the future, as elected by the reporting person. After this transaction, the director beneficially owns 4,613.3964 deferred stock units in direct form, reflecting accumulated deferred equity compensation rather than an open-market purchase or sale.